RxDoctor Payments Data

Mark Aronica, MD

Allergy & Immunology · Cleveland, OHNPI 1124082821

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,190 of the $14,712 with a category attached, or 69.3%. Sanofi US Services Inc. accounts for 62.4% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $7,536, more than ten times the $114 reported in 2019.

$14,712in general payments, 2019–2025

Across 15 payments — averaging $980.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$9K
  • Sanofi-aventis U.S. LLC$5K
  • AstraZeneca$226
  • Sanofi$150
  • Teva Pharmaceuticals USA, Inc.$114
  • GSK$30
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$10,19069%
  • Speaking & faculty fees$3,99027%
  • Food & beverage$5324%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,712 in reported general payments places this provider in the 75th percentile of 128 allergy & immunology providers in Ohio.

See all allergy & immunology providers in Ohio

Medicare billing

Part B allowed, 2024
$15,858
Medicare patients
116
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab14$114,334
HizentraImmun Glob G(Igg)/Pro/Iga 0-5011$96,706
Dupixent PenDupilumab11$42,053
DuleraMometasone/Formoterol26$14,921
Advair HfaFluticasone Propion/Salmeterol11$7,512
Arnuity ElliptaFluticasone Furoate13$6,780
Epinephrine19$3,264
Azelastine Hcl63$1,987
Fluticasone Propionate36$1,224
Albuterol Sulfate HfaAlbuterol Sulfate46$1,207
Ipratropium Bromide31$875
Montelukast Sodium30$444
Famotidine36$436
Prednisone13$36
Levocetirizine Dihydrochloride14$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$30$6,78013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 128 allergy & immunology providers in Ohio.

Other allergy & immunology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →